UT-WYSS-CENTER
11.8.2020 10:02:28 CEST | Business Wire | Press release
The Wyss Center for Bio and Neuroengineering has granted a worldwide license to Blackrock Microsystems to commercialize its neural signal processing and decoding software platform for research and clinical applications. The agreement follows a long-standing collaborative relationship and represents the first of many important neurotechnology developments the Wyss Center and Blackrock Microsystems intend to advance together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005373/en/
“One limitation of neural signal processing applications is that there is no single software platform that directly works with the multiple devices collecting brain signals. Researchers and clinicians have to develop their own software to analyze the signals from a patient, which limits effectiveness and slows down the implementation of solutions to the clinic,” said David Ibanez, Ph.D., Brain Machine Interface Scientist at the Wyss Center. Ibanez has been leading the Wyss Center’s software platform development efforts over recent months.
Optimized for use with implantable, high-channel count brain-computer interfaces (BCIs), the Wyss Center’s high-performance data analysis platform, called NeuroKey, is an important building block for complete real-time neural interface research and clinical applications, including restoration of movement, communication and control of assistive devices.
The medical-grade platform is compatible with commercial hardware and sensors and can be adapted to custom-made devices. NeuroKey has the potential to accelerate BCI technology research and development for clinical deployment in the lab and at home.
“Access to enabling devices at home, would give me greater independence and freedom,” said Ian Burkhart. Known as a BCI Pioneer, Ian has an enabling neural interface developed by Blackrock Microsystems. He sustained a spinal cord injury during a diving accident in 2010. "Currently BCI devices can only be used under extreme supervision in controlled environments, however, this innovation from Blackrock Microsystems and the Wyss Center pushes research to a stage where these devices can advance into the real world.”
The partnership between the Wyss Center and Blackrock Microsystems is a strong example of the Center’s translational approach. It combines the technical talent and research and development efforts of the Center’s staff with the clinical and market knowledge of Blackrock Microsystems, who has been the leading provider of reliable invasive brain computer interface technology to researchers and BCI Pioneers (tetraplegic patients) for more than a decade.
“Blackrock Microsystems is proud to be collaborating with the Wyss Center in an effort to bring life-changing innovation and neuro technology to patients,” said Marcus Gerhardt, MPhil, MA, Blackrock Microsystem’s co-founder and CEO.
“We hope that this is the first of many joint neurotechnology developments with Blackrock Microsystems, that will have a big impact on many people’s lives,” added Wyss Center’s CEO Mary Tolikas, Ph.D., MBA.
ENDS
About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland
The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.
The Wyss Center staff, together with the Center’s academic and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroradiology and neurotechnology, to reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease and to accelerate the development of devices and therapies for unmet medical needs.
The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.
About Blackrock Microsystems LLC
Blackrock Microsystems, based in Salt Lake City, Utah, was founded in 2008 and is the world’s leading provider of technology in the neuroscience, neural engineering, and neural prosthetics space. The company’s technology is at the core of worldwide innovations in Brain-Machine Interfaces (BMI/BCI), implantable bionic technologies and epilepsy diagnostics. Most impactful implantations of the Utah Array have been in some tetraplegic individuals from University of Pittsburgh’s Nathan Copeland, who controlled a prosthetic arm to fist bump US President Barack Obama in 2016; Ohio State University’s Ian Burkhart who is learning to control an automobile, and CalTech’s Nancy Smith who is learning to play a virtual piano. Seemingly easy tasks, all have used the Utah Array to translate their thoughts into action to restore function.
Image
Download
(20 MB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005373/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 07:00:00 CEST | Press release
Phase 2 RAINBOW study data showed that treatment with nizubaglustat in patients with GM2 gangliosidosis (GM2) and Niemann-Pick type C disease (NPC) reduced disease progression and seizure burdenTopline results from the study announced in 2024 demonstrated that nizubaglustat was safe and well tolerated, with encouraging signs of efficacyThe published data further supports the two ongoing registrational Phase 3 studies with nizubaglustat in GM1/GM2 and NPC Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcemen
K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 03:00:00 CEST | Press release
KSGC 2026 provides end-to-end support - from market entry to sustainable growth - positioning Korea as the gateway for Asia expansion South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from ma
Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More4.6.2026 23:46:00 CEST | Press release
The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the
Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4.6.2026 20:15:00 CEST | Press release
- June events include USA trade mission to Norway (Oslo), the EHA Annual Meeting (Stockholm) and BIO International Convention (San Diego) Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers. Vycellix is attending: June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319) To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.
Sodali & Co Appoints Fabio Bianconi as Head of Italy4.6.2026 19:15:00 CEST | Press release
Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, today announced the appointment of Fabio Bianconi as Head of Italy, effective immediately. Fabio succeeds Andrea Di Segni, who will transition into a new role as Senior Relationship Advisor, where he will continue to support key client relationships and strategic initiatives across the firm. Fabio brings deep experience, strong client relationships, and a track record advising on complex mandates in the Italian market. He will lead Sodali’s continued growth and development in Italy, building on the firm’s established position in the region. Aneliya Crawford, Chief Partnerships Officer & Global Head of Shareholder Advisory of Sodali & Co, said: “Andrea has played a central role in the evolution of Sodali over more than two decades, helping establish the firm as a trusted global advisor in corporate governance and shareholder engagement. He built our Italian business into a leader in the market, as reflect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
